Notably, by the treatment with a selective inhibitor (or achieving gene knock-down), we could place FAK activity upstream of Sema6C-induced phenotypic changes and YAP nuclear localization in cancer cells, potentially reflecting a novel mechanism in control of YAP activity. Here, PTK2 is linked to cancer.